Amendments to the Claims:

Please cancel claims 2, 3, 6, 7, 24, 25 and 33-52 without prejudice.

Please amend claims 1, 9, 27, 28 and 32 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.   (Currently Amended) A method for identifying constitutively activating mutations in a receptor or an ion channel, comprising:

   (A)   providing a library of coding sequences for potentially activating mutations of a candidate receptor or ion channel, which library is generated by replacing coding sequences for small or medium side-chain amino acids with coding sequences for large side-chain amino acids, wherein said small or medium side-chain amino acids are located in or proximate transmembrane segment(s) of the receptor or ion channel;

   (B)   expressing said library in mammalian host cells;

   (C)   measuring the activity of the encoded receptor or ion channels in said mammalian host cells;

   (D)   identifying those coding sequence(s) which encoded activated receptors or ion channels.

Claims 2-3   (Canceled)

4.   (Original)   The method of claim 1, wherein the receptor is a multipass transmembrane receptor.

5.   (Original)   The method of claim 4, wherein the receptor is a 7TM receptor selected from

GT\6435755.2
104659-335

the group consisting of: a G-protein coupled receptor, a chemoattractant peptide receptor, a

neuropeptide receptor, a light receptor, a neurotransmitter receptor, and a polypeptide

hormone receptor.

Claims 6-7   (Canceled)

8.   (Original)   The method of claim 1, wherein the activity is measured directly by

determining the level of second messengers generated in response to receptor or ion channel

activation.

9.   (Currently Amended) The method of claim 1, wherein the activity is measured indirectly by

determining the level of transcription from ~~via~~ an indicator gene.

10.   (Original)   The method of claim 9, wherein the indicator gene is an unmodified

endogenous gene.

11.   (Original)   The method of claim 9, wherein the indicator gene is a heterologous reporter

gene, the activation of the transcriptional regulatory element of which is directly or indirectly

regulated by the receptor or ion channel.

12.   (Original)   The method of claim 10 or 11, wherein the level of transcriptional activation

of the indicator gene is amplified by overexpressing one or more intermediate components of the

signaling cascade leading to the activation of the indicator gene.

13.   (Original)   The method of claim 9, wherein the sensitivity of the indicator gene is

modified by manipulating the promoter sequence at the natural locus for the indicator gene.

14.   (Original)   The method of claim 9, wherein the activity of the indicator gene is modified

by manipulating the transcriptional regulatory sequence at the natural locus for the indicator gene.

15.   (Original)   The method of claim 9, wherein the activity of the indicator gene is modified

by replacing the transcriptional regulatory sequence of the endogenous indicator gene with that of a

Applicants: Beachy and Taipale
Application No.: 09/943,641
Filed: August 30, 2001
Page 5

PATENT
Attorney Docket No.: JHU1970-1

heterologous gene.

16.   (Original)   The method of any one of claim 11, 14, or 15, wherein the transcriptional regulatory element is derived from that of immediate early genes.

17.   (Original)   The method of any one of claim 11, 14, or 15, wherein the transcriptional regulatory element is derived from several heterologous genes.

18.   (Original)   The method of claim 11, wherein the reporter gene encodes a gene product selected from the group consisting of: chloramphenicol acetyl transferase, beta-galactosidase, secreted alkaline phosphatase, a gene product which confers a growth signal, and a gene product for growth in media containing aminotriazole or canavanine.

19.   (Original)   The method of claim 1, wherein the small or medium side-chain amino acids are located at the interfaces between transmembrane helices.

20.   (Original)   The method of claim 1, wherein the small or medium side-chain amino acids are selected from the group consisting of: glycine, alanine, and serine.

21.   (Original)   The method of claim 1, wherein the small or medium side-chain amino acids are selected from the group consisting of: asparagine, aspartic acid, cysteine, proline, threonine and valine.

22.   (Original)   The method of claim 1, wherein the large/bulky side-chain amino acids are selected from the group consisting of: tryptophane, leucine, histidine, threonine, and tyrosine.

23.   (Original)   The method of claim 1, wherein the large side-chain amino acids are selected from the group consisting of: asparagine, cysteine, glutamine, isoleucine, methionine, phenylalanine, proline, and valine.

24.   (Canceled)

25.   (Canceled)

26.   (Original)   The method of claim 1, wherein the cell is a mammalian cell.

27.   (Currently Amended) The method of claim 25 1, wherein the cell is selected from the group consisting of: an avian cell, an insect cell, a yeast cell, and a plant cell.

28.   (Currently Amended) The method of claim 25 1, wherein the cell is a pigment cell capable of dispersing or aggregating its pigment in response to an activated receptor or ion channel.

29.   (Original)   The method of claim 1, wherein the mutation is identified as an activating mutation if the activity of the mutant polypeptide increases by at least 2-fold when compared to the activity of the wild-type polypeptide.

30.   (Original)   The method of claim 1, wherein the mutation is identified as an activating mutation if the activity of the mutant polypeptide increases by at least 5-fold when compared to the activity of the wild-type polypeptide.

31.   (Original)   The method of claim 1, wherein the mutation is identified as an activating mutation if the activity of the mutant polypeptide increases by at least 10-fold when compared to the activity of the wild-type polypeptide.

32.   (Currently Amended) A method for identifying constitutively activating mutations in a multipass transmembrane receptor, comprising:

        (A)   providing a library of coding sequences for a multipass transmembrane receptor, which library includes variant sequences which differ from the wild-type sequence of the receptor by one or more point mutations in or proximate a transmembrane segment(s) of the receptor that replace a small or medium amino acid residue with a large amino acid residue;

        (B)   expressing said library in mammalian host cells;

Applicants: Beachy and Taipale
Application No.: 09/943,641
Filed: August 30, 2001
Page 7

PATENT
Attorney Docket No.: JHU1970-1

(C)   measuring the activity of the encoded multipass transmembrane receptor in said mammalian host cells;

(D)   identifying those coding sequence(s) which encoded activated multipass transmembrane receptor.

Claims 33-52 (Canceled)